Ivan Hyep Sells 13,555 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 13,555 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $18.22, for a total value of $246,972.10. Following the completion of the transaction, the chief financial officer owned 145,355 shares of the company’s stock, valued at $2,648,368.10. This trade represents a 8.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ivan Hyep also recently made the following trade(s):

• On Wednesday, March 4th, Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.25, for a total value of $54,074.75.
• On Thursday, January 22nd, Ivan Hyep sold 1,882 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.15, for a total transaction of $34,158.30.

Bicara Therapeutics Trading Down 0.2%

BCAX stock traded down $0.04 during midday trading on Thursday, reaching $18.50. 950,200 shares of the company’s stock traded hands, compared to its average volume of 516,872. The business has a 50-day moving average price of $16.43 and a two-hundred day moving average price of $15.70. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $19.71.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Citigroup started coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They set an “outperform” rating for the company. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. HC Wainwright restated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Wedbush restated an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. Finally, Wells Fargo & Company upped their price objective on Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.33.

Institutional Investors Weigh In On Bicara Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Bicara Therapeutics during the fourth quarter valued at $45,000. Legal & General Group Plc increased its position in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after acquiring an additional 1,474 shares during the last quarter. Larson Financial Group LLC raised its position in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.